EVH Stock Recent News

The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript

Evolent Health, Inc. (NYSE:EVH ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer, Co-Founder & Board Member John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Kevin Caliendo - UBS Unknown speaker - Guggenheim Partners Charles Rhyee - TD Cowen Jeff Garro - Stephens Inc Richard Close - Canaccord Genuity David Larsen - BTIG Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Operator Welcome to the Evolent Earnings Conference Call for the quarter ended September 30th, 2023. As a reminder, this conference call is being recorded.

Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.59 per share a year ago.

WASHINGTON , Oct. 10, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2023 financial results on Thursday, Nov. 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com.

Evolent Health (EVH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Evolent Health, Inc., is a mid-cap solutions provider in the healthcare space that made a major acquisition late last year. The stock is down some 30% from recent highs despite impressive sales growth and solid analyst firm support. Earnings will decline in FY2023 as the company integrates its new operations before rebounding significantly in FY2024.

WASHINGTON , Aug. 8, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences, including meetings with institutional investors and presentations. A live audio-only webcast and replay for these events will be available, if applicable, on the Investor Relations section of Evolent's website at http://ir.evolenthealth.com.

Evolent Health, Inc. (NYSE:EVH ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Seth Frank – Vice President-Investor Relations Seth Blackley – Chief Executive Officer John Johnson – Chief Financial Officer Conference Call Participants Jeff Garro – Stephens Sean Dodge – RBC Capital Ryan Daniels – William Blair Charles Rhyee – TD Cowan David Larsen – BTIG Sandy Draper – Guggenheim Jessica Tassan – Piper Sandler Richard Close – Canaccord Genuity Jailendra Singh – Truist Operator Welcome to the Evolent Earnings Conference Call for the Quarter Ending June 30, 2023. As a reminder, this conference call is being recorded.